$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000147929016000057 Filed on November 04, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$75.00K	$75.00K	$75.00K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.100M	$7.502M	$5.827M
YoY Change	2.75%	28.75%	9.94%
% of Gross Profit
Research & Development	$12.53M	$10.30M	$13.02M
YoY Change	-16.24%	-20.9%	51.35%
% of Gross Profit
Depreciation & Amortization	$380.0K	$370.0K	$510.0K
YoY Change	-7.32%	-27.45%	-15.0%
% of Gross Profit
Operating Expenses	$19.63M	$17.80M	$18.84M
YoY Change	-10.2%	-5.55%	35.56%
Operating Profit		-$17.72M	-$18.77M
YoY Change		-5.57%	35.75%
Interest Expense	-$10.00K	$256.0K	$390.0K
YoY Change	-95.0%	-34.36%	71.05%
% of Operating Profit
Other Income/Expense, Net	-$130.0K	-$138.0K	-$98.00K
YoY Change	18.18%	40.82%	1860.0%
Pretax Income	-$26.80M	-$17.98M	-$19.18M
YoY Change	21.32%	-6.26%	37.2%
Income Tax
% Of Pretax Income
Net Earnings	-$26.80M	-$17.98M	-$19.18M
YoY Change	21.31%	-6.24%	37.19%
Net Earnings / Revenue	-35736.0%	-23970.67%	-25566.67%
Basic Earnings Per Share		-$0.64	-$0.81
Diluted Earnings Per Share	-$950.4K	-$0.64	-$0.81
COMMON SHARES
Basic Shares Outstanding	28.52M shares	28.16M shares	23.76M shares
Diluted Shares Outstanding		28.16M shares	23.76M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$185.5M	$201.3M	$141.9M
YoY Change	-26.48%	41.86%	-24.32%
Cash & Equivalents	$63.50M	$130.5M	$90.49M
Short-Term Investments	$122.0M	$70.80M	$51.40M
Other Short-Term Assets	$163.0K	$7.400M	$1.600M
YoY Change	-38.95%	362.5%	1760.47%
Inventory
Prepaid Expenses	$978.0K
Receivables	$128.0K
Other Receivables	$53.00K
Total Short-Term Assets	$192.7M	$208.7M	$143.5M
YoY Change	-24.12%	45.42%	-24.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.59M	$17.39M	$19.25M
YoY Change	-46.29%	-9.71%	10.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$2.400M
YoY Change	-100.0%	-100.0%
Other Assets	$500.0K	$213.0K	$6.000K
YoY Change		3450.0%	-96.72%
Total Long-Term Assets	$11.67M	$18.18M	$22.02M
YoY Change	-46.64%	-17.44%	22.24%
TOTAL ASSETS
Total Short-Term Assets	$192.7M	$208.7M	$143.5M
Total Long-Term Assets	$11.67M	$18.18M	$22.02M
Total Assets	$204.4M	$226.9M	$165.5M
YoY Change	-25.91%	37.06%	-20.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.754M	$2.871M	$2.731M
YoY Change	41.29%	5.13%	2.44%
Accrued Expenses	$12.42M	$11.31M	$5.990M
YoY Change	98.85%	88.75%	80.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.500M	$3.300M	$3.000M
YoY Change	12.9%	10.0%	-65.91%
Total Short-Term Liabilities	$19.65M	$17.52M	$11.74M
YoY Change	63.22%	49.21%	-20.4%
LONG-TERM LIABILITIES
Long-Term Debt	$1.900M	$2.800M	$6.200M
YoY Change	-64.15%	-54.84%	588.89%
Other Long-Term Liabilities	$100.0K	$100.0K	$5.200M
YoY Change		-98.08%	-1.89%
Total Long-Term Liabilities	$100.0K	$100.0K	$11.40M
YoY Change		-99.12%	83.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.65M	$17.52M	$11.74M
Total Long-Term Liabilities	$100.0K	$100.0K	$11.40M
Total Liabilities	$27.29M	$26.14M	$23.16M
YoY Change	20.91%	12.89%	10.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$421.5M	-$394.7M	-$310.2M
YoY Change	26.87%	27.26%	26.82%
Common Stock	$598.7M	$595.4M	$452.5M
YoY Change	2.24%	31.58%	4.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$177.1M	$200.7M	$142.4M
YoY Change
Total Liabilities & Shareholders Equity	$204.4M	$226.9M	$165.5M
YoY Change	-25.91%	37.06%	-20.78%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$26.80M	-$17.98M	-$19.18M
YoY Change	21.31%	-6.24%	37.19%
Depreciation, Depletion And Amortization	$380.0K	$370.0K	$510.0K
YoY Change	-7.32%	-27.45%	-15.0%
Cash From Operating Activities	-$13.47M	-$14.35M	-$13.71M
YoY Change	-18.12%	4.67%	8.04%
INVESTING ACTIVITIES
Capital Expenditures	-$520.0K	-$160.0K	-$560.0K
YoY Change	8.33%	-71.43%	-72.28%
Acquisitions
YoY Change
Other Investing Activities	-$52.33M	$93.01M	-$1.010M
YoY Change	-5788.04%	-9308.91%
Cash From Investing Activities	-$52.84M	$92.84M	-$1.570M
YoY Change	-12109.09%	-6013.38%	-22.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-670.0K	-660.0K	9.350M
YoY Change	-100.53%	-107.06%	-942.34%
NET CHANGE
Cash From Operating Activities	-13.47M	-14.35M	-13.71M
Cash From Investing Activities	-52.84M	92.84M	-1.570M
Cash From Financing Activities	-670.0K	-660.0K	9.350M
Net Change In Cash	-66.98M	77.83M	-5.930M
YoY Change	-160.32%	-1412.48%	-62.54%
FREE CASH FLOW
Cash From Operating Activities	-$13.47M	-$14.35M	-$13.71M
Capital Expenditures	-$520.0K	-$160.0K	-$560.0K
Free Cash Flow	-$12.95M	-$14.19M	-$13.15M
YoY Change	-18.91%	7.91%	23.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28515070	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2015Q4	rvnc	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	1751000	USD
CY2016Q3	rvnc	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	0	USD
CY2016Q3	rvnc	Cash Cash Equivalentsand Investments CashCashEquivalentsandInvestments	201300000	USD
	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2015Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	5346000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1949000	USD
	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	5000	USD
CY2016Q3	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	0	USD
CY2016Q3	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	2836000	USD
CY2015Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	3135000	USD
CY2016Q3	rvnc	Financing Obligation Current FinancingObligationCurrent	3339000	USD
CY2016Q3	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	5939000	USD
CY2016Q3	rvnc	Financing Obligation Future Minimum Payments Duein Three Years FinancingObligationFutureMinimumPaymentsDueinThreeYears	949000	USD
CY2016Q3	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	3936000	USD
CY2016Q3	rvnc	Financing Obligation Future Minimum Payments Next Twelve Months FinancingObligationFutureMinimumPaymentsNextTwelveMonths	1054000	USD
CY2015Q3	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	13000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	60000	USD
CY2016Q3	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-167000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-595000	USD
CY2015Q3	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	0	USD
	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	39000	USD
CY2016Q3	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	0	USD
	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	0	USD
CY2015Q3	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	0	USD
	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	0	USD
CY2015Q3	rvnc	Noncash Interest Expense NoncashInterestExpense	126000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	270000	USD
CY2016Q3	rvnc	Noncash Interest Expense NoncashInterestExpense	98000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	315000	USD
CY2016Q3	rvnc	Working Capital Surplus WorkingCapitalSurplus	191200000	USD
	rvnc	Writeoffof Fixed Assets WriteoffofFixedAssets	28000	USD
	rvnc	Writeoffof Fixed Assets WriteoffofFixedAssets	0	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2657000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2871000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-364000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1029000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6245000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11306000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-40000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	585537000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	595411000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2590000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7314000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2755000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8984000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	39000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2015Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2016Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2015Q4	us-gaap	Assets Assets	275822000	USD
CY2016Q3	us-gaap	Assets Assets	226857000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	253963000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	208679000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	198186000	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	197519000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	16000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	40000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	198226000	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	197503000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	50688000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	70770000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52439000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	70770000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171032000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90494000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201615000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130481000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-80538000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-71134000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28288464	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28515161	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28288464	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28515161	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	29000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19153000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51372000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18110000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62412000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	84000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3773000	USD
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3681000	USD
	us-gaap	Depreciation Depreciation	1586000	USD
	us-gaap	Depreciation Depreciation	1068000	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1414000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-477000	USD
CY2016Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2009000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	200000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3096000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5821000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-24000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-152000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	134000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.22
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.22
CY2016Q2	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	200000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	200000	USD
CY2015Q3	us-gaap	Financing Interest Expense FinancingInterestExpense	126000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	226000	USD
CY2016Q3	us-gaap	Financing Interest Expense FinancingInterestExpense	98000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	315000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5852000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	145000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	940000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	144000	USD
CY2016Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	306000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	390000	USD
	us-gaap	Interest Expense InterestExpense	834000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	256000	USD
	us-gaap	Interest Expense InterestExpense	857000	USD
CY2015Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	264000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	564000	USD
CY2016Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	158000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	542000	USD
	us-gaap	Interest Paid InterestPaid	564000	USD
	us-gaap	Interest Paid InterestPaid	542000	USD
CY2015Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	68000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2015Q4	us-gaap	Liabilities Liabilities	22570000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	26142000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275822000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226857000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12037000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17516000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	1751000	USD
CY2016Q3	us-gaap	Long Term Investments LongTermInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15541000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1974000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56861000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22801000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39218000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46400000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46359000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-19175000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-51382000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-18000000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-17978000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-62468000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-62500000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19175000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-51382000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17978000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62468000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19175000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-51382000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17978000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-62468000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	95000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	29000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	18843000	USD
	us-gaap	Operating Expenses OperatingExpenses	50756000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1307000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5763000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	17798000	USD
	us-gaap	Operating Expenses OperatingExpenses	61775000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18768000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50531000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17723000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61550000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	44633000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5578000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5394000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	26591000	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3900000	USD
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4000000	USD
	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	213000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	22000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-132000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	56000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-98000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-221000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-138000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-406000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	243000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	762000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	359000	USD
CY2016Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	54087000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	159754000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2849000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1152000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1625000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7428000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10154000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2016Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2652000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	139050000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	738000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1250000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19708000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17385000	USD
CY2016Q3	us-gaap	Purchase Obligation PurchaseObligation	14900000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1768000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	2622000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13016000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32573000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10296000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37851000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2000000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	35000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-332273000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-394741000	USD
CY2015Q3	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	225000	USD
CY2016Q3	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	225000	USD
	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	9831000	USD
	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	0	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5827000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18183000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7502000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21975000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7314000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8984000	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	50688000	USD
CY2016Q3	us-gaap	Short Term Investments ShortTermInvestments	70770000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	253252000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	200715000	USD
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2016Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2015Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2016Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2015Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2016Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23755199	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23625869	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28160458	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28085541	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23755199	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23625869	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28160458	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28085541	shares
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation, or Medicis, entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational, injectable botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT002 injectable and RT001 topical from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> in 2014, and (iii) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT002 injectable or RT001 topical by the Company, or Product Approval Payment. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The proceeds sharing arrangement payment derivative in (ii) above was settled upon completion of our initial public offering, or IPO. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.5</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">0.95%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">9.00%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2020. The Company did not make any payments under the Product Approval Payment during </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of Condensed Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include accruals, stock-based compensation, the fair value of derivative liability associated with the Medicis settlement, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001479290-16-000057-index-headers.html	Edgar Link	pending
0001479290-16-000057-index.html	Edgar Link	pending
0001479290-16-000057.txt	Edgar Link	pending
0001479290-16-000057-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20160930.xml	Edgar Link	completed
rvnc-20160930.xsd	Edgar Link	pending
rvnc-20160930_cal.xml	Edgar Link	unprocessable
rvnc-20160930_def.xml	Edgar Link	unprocessable
rvnc-20160930_lab.xml	Edgar Link	unprocessable
rvnc-20160930_pre.xml	Edgar Link	unprocessable
rvnc-q316exhibit311.htm	Edgar Link	pending
rvnc-q316exhibit312.htm	Edgar Link	pending
rvnc-q316exhibit321.htm	Edgar Link	pending
rvnc-q316exhibit322.htm	Edgar Link	pending
rvncq31610q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2016 Q4 Form 10-Q Financial Statement

#000147929016000057 Filed on November 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2016 Q4 Form 10-Q Financial Statement

#000147929016000057 Filed on November 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc